Russell Investments Group
TVTX icon

Russell Investments Group’s Travere Therapeutics TVTX Stock Holding History

Russell Investments Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.96M Sell
234,265
-51,046
-18% -$1.53M 0.01% 1146
2025
Q4 		$10.9M Buy
285,311
+63,054
+28% +$2.05M 0.01% 867
2025
Q3 		$5.31M Sell
222,257
-15,463
-7% -$291K 0.01% 1280
2025
Q2 		$3.52M Buy
237,720
+12,784
+6% +$212K ﹤0.01% 1419
2025
Q1 		$4.03M Buy
224,936
+59,007
+36% +$1.2M 0.01% 1282
2024
Q4 		$2.89M Buy
165,929
+4,663
+3% +$82.5K ﹤0.01% 1468
2024
Q3 		$2.26M Sell
161,266
-4,791
-3% -$49.9K ﹤0.01% 1632
2024
Q2 		$1.36M Sell
166,057
-18,566
-10% -$125K ﹤0.01% 1832
2024
Q1 		$1.42M Buy
184,623
+81,611
+79% +$689K ﹤0.01% 1825
2023
Q4 		$926K Buy
103,012
+5,499
+6% +$40K ﹤0.01% 2001
2023
Q3 		$872K Buy
97,513
+771
+0.8% +$10.9K ﹤0.01% 2003
2023
Q2 		$1.49M Buy
96,742
+781
+0.8% +$14.2K ﹤0.01% 1727
2023
Q1 		$2.16M Buy
95,961
+42,756
+80% +$909K ﹤0.01% 1536
2022
Q4 		$1.12M Buy
53,205
+22,209
+72% +$471K ﹤0.01% 1913
2022
Q3 		$762K Sell
30,996
-12,580
-29% -$325K ﹤0.01% 2057
2022
Q2 		$1.05M Sell
43,576
-4,568
-9% -$115K ﹤0.01% 1940
2022
Q1 		$1.24M Sell
48,144
-19,137
-28% -$508K ﹤0.01% 1854
2021
Q4 		$2.09M Sell
67,281
-18,575
-22% -$523K ﹤0.01% 1781
2021
Q3 		$2.08M Sell
85,856
-14,787
-15% -$272K ﹤0.01% 1812
2021
Q2 		$1.47M Sell
100,643
-57,832
-36% -$1.14M ﹤0.01% 2116
2021
Q1 		$3.96M Buy
+158,475
New +$4.38M 0.01% 1479
2020
Q4 		– Sell
-131,076
Closed -$2.42M – 3191
2020
Q3 		$2.42M Sell
131,076
-18,155
-12% -$353K 0.01% 1562
2020
Q2 		$3.04M Buy
149,231
+41,914
+39% +$667K 0.01% 1391
2020
Q1 		$1.56M Buy
107,317
+24,871
+30% +$374K ﹤0.01% 1601
2019
Q4 		$1.17M Buy
82,446
+57,746
+234% +$738K ﹤0.01% 2028
2019
Q3 		$286K Buy
24,700
+13,355
+118% +$221K ﹤0.01% 2477
2019
Q2 		$227K Sell
11,345
-230,896
-95% -$4.56M ﹤0.01% 2488
2019
Q1 		$5.48M Buy
242,241
+12,860
+6% +$284K 0.01% 1189
2018
Q4 		$5.19M Sell
229,381
-4,146
-2% -$103K 0.01% 1131
2018
Q3 		$6.71M Buy
233,527
+34,150
+17% +$976K 0.01% 1157
2018
Q2 		$5.42M Buy
199,377
+186,932
+1,502% +$4.98M 0.01% 1242
2018
Q1 		$279K Sell
12,445
-2,591
-17% -$61.7K ﹤0.01% 2610
2017
Q4 		$326K Buy
15,036
+7,637
+103% +$175K ﹤0.01% 2563
2017
Q3 		$184K Sell
7,399
-670
-8% -$14.8K ﹤0.01% 2681
2017
Q2 		$157K Sell
8,069
-5,865
-42% -$106K ﹤0.01% 2733
2017
Q1 		$257K Sell
13,934
-6,195
-31% -$121K ﹤0.01% 2638
2016
Q4 		$387K Buy
+20,129
New +$412K ﹤0.01% 2548

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Russell Investments Group's TVTX Position: Q1 2026 in Review

Russell Investments Group reduced its Travere Therapeutics (TVTX) stake by 18% in Q1 2026, selling an estimated $1.53M and leaving 234,265 shares worth $6.96M. The position accounts for 0.01% of the portfolio, ranked #1146.

Russell Investments Group first reported a position in TVTX in Q4 2016 and has held it in 37 quarters since. The position peaked at $10.9M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Russell Investments Group held 234,265 shares of Travere Therapeutics worth $6.96M as of Q1 2026.
  • Russell Investments Group sold 51,046 Travere Therapeutics shares in Q1 2026, an estimated $1.53M.
  • Travere Therapeutics made up 0.01% of Russell Investments Group's portfolio in Q1 2026, its #1146 holding.
  • Russell Investments Group first reported a position in Travere Therapeutics in Q4 2016 and has held it in 37 quarters since.
  • Russell Investments Group's Travere Therapeutics position peaked at $10.9M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.